Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10051324HBVENSG00000167601.12protein_codingAXLYesNo558M0R0W6
P30530
TVIS30077070HIVENSG00000167601.12protein_codingAXLYesNo558M0R0W6
P30530
TVIS30020487HIVENSG00000167601.12protein_codingAXLYesNo558M0R0W6
P30530
TVIS20009591HPVENSG00000167601.12protein_codingAXLYesNo558M0R0W6
P30530
TVIS44003252HTLV-1ENSG00000167601.12protein_codingAXLYesNo558M0R0W6
P30530
TVIS44002987HTLV-1ENSG00000167601.12protein_codingAXLYesNo558M0R0W6
P30530
TCGA Plot Options
Drug Information
GeneAXL
DrugBank IDDB12141
Drug NameGilteritinib
Target IDBE0009412
UniProt IDP30530
Regulation Typeinhibitor
PubMed IDs27775694; 26279055; 28516360
CitationsAntar A, Otrock ZK, El-Cheikh J, Kharfan-Dabaja MA, Battipaglia G, Mahfouz R, Mohty M, Bazarbachi A: Inhibition of FLT3 in AML: a focus on sorafenib. Bone Marrow Transplant. 2017 Mar;52(3):344-351. doi: 10.1038/bmt.2016.251. Epub 2016 Oct 24.@@Thom C: Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients. Future Oncol. 2015 Sep;11(18):2499-501. doi: 10.2217/fon.15.188. Epub 2015 Aug 17.@@Mori M, Kaneko N, Ueno Y, Yamada M, Tanaka R, Saito R, Shimada I, Mori K, Kuromitsu S: Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017 Oct;35(5):556-565. doi: 10.1007/s10637-017-0470-z. Epub 2017 May 17.
GroupsApproved; Investigational
Direct ClassificationPhenylpiperidines
SMILESCCC1=C(NC2CCOCC2)N=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)C(=N1)C(N)=O
Pathways
PharmGKB
ChEMBLCHEMBL3301622